Lyrica
Product Images NDC 54868-5662

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 54868-5662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle)

The packaging label for Lyrica 100 mg pregabalin capsules from Physicians Total Care, Inc. shows a box containing 30 capsules. It includes cautions about prescription dispensing, storage instructions to keep at 20 to 25°C, and warnings to keep out of reach of children. The label features the NDC number, barcode, lot number, and expiration date areas.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle)

Lyrica 150 mg capsules packaging label by Physicians Total Care, Inc. The label specifies the product name, strength, dosage form (pregabalin capsules), and package size of 30 capsules. It includes cautions against dispensing without prescription and handling/storage instructions.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle)

Packaging label for Lyrica 200 mg capsules distributed by Physicians Total Care, Inc. The label includes the National Drug Code (NDC) 54868-6063-1, lot number 0000, and an expiration date listed as 01/60. The manufacturer is Pfizer Pharmaceuticals, LLC, located in Vega Baja, Puerto Rico. The label also contains a barcode and a small vial icon with the letter V inside.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle)

Lyrica 25 mg capsules packaging label from Physicians Total Care, Inc. Contains 30 capsules of pregabalin. The label includes caution about federal law prohibiting dispensing without prescription and storage instructions. Also displays lot number, expiration date, and manufacturer information.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle)

Lyrica 50 mg capsules label from Physicians Total Care, Inc. The label states each capsule contains 50 mg of pregabalin and the bottle contains 30 capsules. It includes caution about federal law prohibiting dispensing without a prescription and storage instructions to keep the bottle tightly closed and stored at controlled room temperature.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle)

Lyrica 75 mg pregelin capsules label by Physicians Total Care, Inc. The label states the package contains 30 capsules, each capsule containing 75 mg. It includes prescription cautionary notes and storage instructions, along with regulatory and lot information.*

FDA Label Image

Figure (Lyrica 01)

A mathematical formula for calculating creatinine clearance (CLCr), which includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor adjustment of 0.85 for female patients. The formula is presented in a fraction layout with age and weight multiplied and divided by serum creatinine times 72.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of Lyrica. The image shows a molecular formula representation including functional groups such as an amino group (NH2) and a carboxyl group (CO2H), indicative of the active ingredient in Lyrica.*

FDA Label Image

Figure 1 (Lyrica 03)

Line chart depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg three times a day doses compared to placebo. The chart shows declining patient improvement percentages as pain improvement increases.*

FDA Label Image

Figure 2 (Lyrica 04)

A line chart showing percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day with placebo, illustrating patient response differences across pain improvement percentages.*

FDA Label Image

Figure 3 (Lyrica 05)

A line chart showing the percent of patients improved plotted against percent improvement in pain from baseline for Lyrica (pregabalin) at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to a placebo. The graph illustrates higher patient improvement rates with increasing pregabalin doses.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating their respective efficacy in pain improvement.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph showing the percent improvement in pain from baseline versus the percent of patients improved for Lyrica (pregabalin) at 50 mg and 100 mg taken three times a day, compared to placebo. The graph illustrates the relationship between pain improvement levels and patient response rates for each treatment group.*

FDA Label Image

Figure 6 (Lyrica 08)

This image shows two bar graphs labeled 'Study E1' and 'Study E3' comparing responder rates (%) for placebo and varying dosages of a drug. The x-axis indicates dosage groups and sample sizes, while the y-axis represents responder rate percentages. Statistically significant differences versus placebo are noted.*

FDA Label Image

Figure 7 (Lyrica 09)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day. It compares results across four studies labeled E1BD, E2TID, E3BD, and E3TID, showing trends in seizure reduction with increasing doses. Significant p-values are noted on the graph.*

FDA Label Image

Figure 8 (Lyrica 10)

A line graph depicting the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis for Lyrica (pregabalin) at doses of 300 mg, 450 mg, and 600 mg daily compared to placebo. The graph shows response curves for each dose and placebo, illustrating patient improvement distribution.*

FDA Label Image

Figure 9 (Lyrica 11)

A line graph depicting the estimated percentage of subjects without LTR (long-term response) over 180 days for Lyrica (pregabalin) compared to placebo. The graph shows two lines: a solid line for pregabalin and a dashed line for placebo, representing the proportion of subjects without LTR over time.*

FDA Label Image

Figure 10 (Lyrica 12)

A line graph comparing the percent of subjects improved on the y-axis against the percent improved from baseline to week 12 BOCF on the x-axis. Two lines are shown: one for Pregabalin and one for Placebo, illustrating the difference in improvement between the two groups over the specified range.*

FDA Label Image

Figure 11 (Lyrica 13)

A line graph showing the percent of subjects improved over a range of percent improvement from baseline to week 16, comparing Pregabalin and Placebo. The x-axis displays percent improved from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100. Two lines illustrate the comparison: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin showing a higher percent improved across the range.*

FDA Label Image

Logo (Lyrica 14)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.